New guidelines for progressive supranuclear palsy provide very specific and sensitive criteria that allow for identification of clinical features of the disease at much earlier stages.
Dextromethorphan is thought to have an impact on all 3 therapeutic pathways for dyskinesia.
Jori Fleisher, MD, MSCE, of New York University School of Medicine, discusses her research on an interdisciplinary home visit program for patients with advanced Parkinson's disease. Scroll below the video for the full transcript.
De novo likely gene disrupting variants were highly overrepresented in the Tourette's cases compared with unaffected parent and sibling sample controls.
The results add to the growing body of evidence in support of deep brain stimulation for refractory Tourette syndrome.
A patient should be notified of the possibility of developing an ICD before initiating any dopaminergic treatment for PD, particularly dopamine agonists.
A 150-year-old drug, apomorphine, may reduce off time in patients with Parkinson's disease.
Previous animal model studies have shown PEA to be beneficial in neuroinflammation and provide neuroprotection.
Transcranial Doppler during head-up tilting may be useful for evaluating dizziness.
People with HBV were 76% more likely and those with HCV were 51% more likely to develop PD than people in the comparison group.
Valbenazine is the first drug approved for the treatment of tardive dyskinesia, an adverse effect associated with the use of some antipsychotic medications.
A significant association was found between the apnea-hypopnea index and Epworth Sleepiness Scale scores.
Researchers have developed an assay that accurately identifies small quantities of α-synuclein in cerebrospinal fluid.
There were slower declines in health-related quality of life and mobility when exercise was increased by 30 minutes/week.
The US FDA has approved safinamide as adjunctive therapy in Parkinson's disease to increase "on" time
A 10-month-old girl admitted to PICU with sudden onset of movement disorder was found to have ingested a foreign body.
While their are other factors more strongly associated with risk of cerebral palsy, maternal obesity is modifiable and therefore should be studied further.
Improvements in excessive daytime sleepiness and daytime alertness were observed in the bright light therapy group.
Neurofilament light chain, a blood biomarker, demonstrated high accuracy for distinguishing atypical parkinsonian disorders from Parkinson's disease.
Comorbid psychological conditions affect cognitive function in Parkinson's disease, and treatment can be complicated by overlapping symptoms.
New findings suggest that dysregulation of mitochondrial DNA homeostasis may be a key factor in the pathogenesis of neuronal loss in people with Parkinson's disease.
During cognitive co-activation, the levodopa effect was significantly smaller.
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
A combination of age and clinical scores better predicted cognitive impairment than age alone.
Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.
Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.
A powdered version of the common treatment may help to relieve "off" periods.
The small study documented several cases of denervation and increased thermal thresholds in patients treated with LCIG.
Pharmacologic intervention is the current standard of care for Parkinson's disease, yet medications frequently fail to control some symptoms, including tremor and postural instability.
The researchers found that GBA carriers were at greater risk for dementia and death (hazard ratios, 3.16 and 1.85, respectively) than non-carriers.
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Telestroke Treatment With IV tPA: How Long Is the Window of Opportunity?
- Hypothalamus May Play a Central Role in Chronic Migraine
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia
- The Handoff: Your Week in Neurology News - 5/25/17
- In Multiple Sclerosis, Hand Strength May Indicate Disease Status